jili369 casino login philippines
LIVERPOOL, England (AP) — Kylian Mbappe hoped his move to Real Madrid would finally see him end his wait to win the Champions League. Instead, the France international and defending champion Madrid are in danger of being eliminated from European club soccer's elite tournament at the first stage after Wednesday's 2-0 loss to Liverpool leaves them in a fight just to make the playoffs for the next round. And if Madrid does make an early exit, Mbappe may look back on a miserable night at Anfield where he was humbled by a young defender and then missed a penalty that would have leveled the score. World Cup winner Mbappe looked a shadow of himself against a Liverpool team that leads the way in the Premier League and the Champions League this season. He was brought crashing down by a crunching tackle from 21-year-old right back Conor Bradley when threatening to burst through on goal in the first half — sparking a huge cheer from the home crowd. It got worse for Mbappe after the break when he had the chance to make it 1-1 from the penalty spot after Alexis Mac Allister had given six-time European champion Liverpool the lead. But with Caoimhin Kelleher to beat, he saw his effort pushed away by Liverpool's back-up goalkeeper. Mohamed Salah also missed a spot kick of his own, but substitute Cody Gakpo doubled the home team's advantage. Record 15-time European Cup winner Madrid is 24th in the new-look 36-team league phase of the Champions League. The to the round of 16, while teams ranked ninth to 24th go into a playoff. Victory saw new Liverpool head coach Arne Slot manage something his predecessor Jurgen Klopp never could by beating Real in the Champions League. His team extended its perfect record in the competition and is top of the standings after five games. Each team plays eight games in the opening phase. Madrid plays Atalanta next month and Liverpool faces Girona. ___ James Robson is at ___ AP soccer: James Robson, The Associated PressSUGAR LAND, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Applied Optoelectronics, Inc. ("AOI") AAOI , a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, telecom and fiber-to-the-home (FTTH) markets, today announced that it has filed a complaint for patent infringement against Accelight Technologies, Inc. (ATI) in the U.S. District Court for the Northern District of California, Case No.: 3:24-cv-09041. The complaint, filed December 13, 2024, in the U.S. District Court for the Northern District of California, alleges that at least the ATI 100G QSFP28 LR4, ATI 400G QSFP-DD SR8, ATI 100G QSFP28 CWDM4, ATI 400G QSFP-DD FR4, and ATI 400G QSFP-DD DR4 infringe one or more of the asserted Applied Optoelectronic, Inc. (AOI) optical transceiver patents. "AOI filed this lawsuit because we believe ATI is infringing several of our key optical transceiver patents. AOI has invested significantly in research and development and will continue to enforce its IP rights against alleged infringers to protect those rights," said Dr. Thompson Lin, Applied Optoelectronics, Inc. Founder, President and Chief Executive Officer. In the complaint, AOI is seeking monetary damages from ATI and a permanent injunction. About Applied Optoelectronics, Inc. Applied Optoelectronics, Inc. (AOI) is a leading developer and manufacturer of advanced optical products, including components, modules and equipment. AOI's products are the building blocks for broadband fiber access networks around the world, where they are used in the internet datacenter, CATV broadband, telecom and FTTH markets. AOI supplies optical networking lasers, components and equipment to tier-1 customers in all four of these markets. In addition to its corporate headquarters, wafer fab and advanced engineering and production facilities in Sugar Land, TX, AOI has engineering and manufacturing facilities in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com . Investor Relations Contact: The Blueshirt Group, Investor Relations Monica Gould +1-212-871-3927 ir@ao-inc.com Cassidy Fuller +1-415-217-4968 ir@ao-inc.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Brock Purdy will miss Sunday's game for the 49ers with a shoulder injury
Chicago Bulls’ Coby White has the green light from behind the arc, and he loves it.WASHINGTON — Just a few weeks ago, the path ahead for the Federal Reserve looked straightforward: With inflation cooling and the job market slowing, the Fed appeared on track to steadily cut interest rates. In September, its officials predicted that they would reduce their benchmark rate four times next year, on top of three rate cuts this year. Yet that outlook has swiftly changed. Several surprisingly strong economic reports, combined with President-elect Donald Trump’s policy proposals, have led to a decidedly more cautious tone from the Fed that could mean fewer cuts and higher interest rates than had been expected. Fewer rate cuts would likely mean continued high mortgage rates and other borrowing costs for consumers and businesses. Auto loans would remain expensive. Small businesses would still face high loan rates. In a speech last week in Dallas, Chair Jerome Powell made clear that the Fed isn’t necessarily inclined to cut rates each time it meets every six weeks. “The economy is not sending any signals that we need to be in a hurry to lower rates,” Powell said. “The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully.” His comments were widely seen as signaling potentially fewer rate cuts in 2025, a view that sent stock prices falling after they had surged with Trump’s election. Trump has proposed higher tariffs on all imports as well as mass deportations of undocumented immigrants — steps that economists say would worsen inflation. The president-elect has also proposed a menu of tax cuts and deregulation, which might help spur economic growth but would also fan inflation if businesses couldn’t find enough workers to meet increased consumer demand. And recent economic data suggests that inflation pressures could prove more persistent and economic growth more resilient than was thought just a few months ago. At his most recent news conference, Powell suggested that the economy could even accelerate in 2025. Wall Street traders and some economists now envision just two, rather than four, rate cuts next year. And while the Fed will likely cut its key rate when it meets in mid-December, traders foresee a nearly even likelihood that the central bank could leave the rate unchanged. “I absolutely would anticipate that they’ll ease up on the pace of cuts,” said Jim Baird, chief investment officer at Plante Moran Financial Advisors. “The potential for growth to remain strong — that has to call into question whether they will feel either the need or ability to cut rates at the pace they had previously forecast.” Economists at Bank of America expect annual inflation to remain “stuck” above 2.5%, higher than the Fed’s 2% target level, in part given the likelihood that Trump’s economic proposals, if carried out, would fuel price pressures. The economists now foresee just three rate reductions in the coming months, in December, March and June. And they expect the Fed to stop easing credit once its benchmark rate, now at 4.6%, reaches 3.9%. Krishna Guha, an analyst at investment bank Evercore ISI, wrote last week that, “We think the looming Trump presidency is helping to drive a change in tone from the Fed — including Powell — towards a warier and more hedged posture on the pace and extent of further cuts.” Trump has vowed to impose a 60% tariff on all Chinese goods and a “universal’’ tariff of 10% or 20% on everything else that enters the United States. On Wednesday, a top executive at Walmart, the world’s largest retailer, warned that Trump’s tariff proposals could force the company to raise prices on imported goods. “Tariffs will be inflationary for customers,” John David Rainey, Walmart’s chief financial officer, told The Associated Press. Other consumer goods and retail companies, including Lowe’s, Stanley Black & Decker, and Columbia Sportswear, have issued similar warnings. In trying to gauge the right level for interest rates, the Fed’s policymakers face a significant obstacle: They don’t know how much further they can reduce rates before reaching a level that neither stimulates nor restrains the economy — what’s called the “neutral rate.” The officials don’t want to cut rates so low as overheat the economy and reignite inflation. Nor do they want to keep rates so high as to damage the job market and the economy and risk a recession. An unusually wide divergence has developed among the 19 officials on the Fed’s rate-setting committee as to where the neutral rate is. In September, the officials collectively projected that the neutral rate lies between 2.4% and 3.8%. Lorie Logan, president of the Federal Reserve Bank of Dallas, has noted that that range is twice as large as it was two years ago. In a recent speech, Logan suggested that the Fed’s benchmark rate might be only slightly above the neutral level now. If so, that would mean few additional rate cuts are needed. Other officials disagree. In a recent interview with The Associated Press, Austan Goolsbee, president of the Fed’s Chicago branch, said he thought the neutral rate is much lower than the Fed’s current rate. If so, many more rate cuts would likely be appropriate. “I still think we’re far from what anybody thinks is neutral,” Goolsbee said. “We still got a ways to come down.” Perhaps the biggest unknown is how Trump’s proposals on tariffs, deportations and tax cuts will shape the Fed’s rate decisions. Powell has stressed that the Fed won’t change its policymaking until it’s clear what changes the new administration will actually implement. As is customary for the Fed, though, Powell avoided commenting directly on presidential policies. But he did acknowledge that the Fed’s economists are assessing the potential effects of a Trump presidency. “We don’t actually really know what policies will be put in place,” Powell said. “We don’t know over what timeframe.” Another factor is that the economy is much different now than when Trump first took office in January 2017. With unemployment lower than it was then, economists say, additional stimulus through tax cuts might create more demand than the economy can handle, possibly fueling inflation. Tax cuts, “starting from an economy close to full employment, will lead to inflation and, by implication, higher Fed policy rates and a stronger dollar,” Olivier Blanchard, a former top economist at the International Monetary Fund and senior fellow at the Peterson Institute for International Economics, wrote in a recent commentary. In 2018, when Trump imposed a slew of tariffs on imports from China, as well as on steel, aluminum and washing machines, Fed economists produced an analysis of how they should respond. Their conclusion? As long as the tariffs were one-time increases and the public didn’t expect inflation to rise, the Fed wouldn’t have to respond by raising its key rate. Yet last week, Powell acknowledged that the economy was different now, with inflation a bigger threat. “Six years ago,” he said, “inflation was really low and inflation expectations were low. And now, we’ve come way back down, but we’re not back where we were. It’s a different situation.”
CHICAGO, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is proud to announce the recipients of the 2024 FSR Cardiac Sarcoidosis Grant, providing $200,000 in funding to advance groundbreaking research aimed at improving the diagnosis, management, and treatment of cardiac sarcoidosis and doubling FSR’s investment from 2023. FSR has awarded two grants, each in the amount of $100,000, to Dr. Eliot Peyster, MD, MSc, Assistant Professor of Medicine at the University of Pennsylvania, and Dr. Ravi Karra, MD, MHS, Associate Professor of Medicine and Pathology at Duke University. These grants support innovative projects designed to improve diagnostic accuracy and clinical care for cardiac sarcoidosis patients. Dr. Peyster’s research project, Establishing a True Gold Standard for Cardiac Sarcoidosis Diagnosis with Quantitative Multi-marker Immunofluorescence , applies advanced spatial biology techniques to create a new diagnostic gold standard for cardiac sarcoidosis, leveraging quantitative multi-marker immunofluorescence. His expertise spans cardiovascular diseases, heart failure, and translational research, with a focus on adapting cutting-edge technologies to improve patient care. “This generous award from the FSR will enable us to test a novel, modern, and very promising new approach to diagnosing cardiac sarcoidosis,” says Dr. Peyster. “The work we will perform as part of this award has the potential to be practice-changing and will hopefully lead to earlier disease detection and better outcomes for patients.” Dr. Karra’s research project, Repurposing 99mTc-Tilmanocept Imaging for Cardiac Sarcoidosis , focuses on adapting macrophage-specific imaging agents to improve cardiac sarcoidosis diagnosis and monitoring. His translational program at Duke University combines developmental biology and epidemiology to advance early-phase clinical trials and improve care for heart failure patients. “With generous support from the Foundation for Sarcoidosis Research, we are excited to test whether an imaging agent specific to macrophages can be used to better diagnose and follow cardiac sarcoidosis,” says Dr. Karra. “This work is part of a bench-to-bedside approach from my lab and has the potential to address a significant, unmet need in the field of sarcoidosis.” "We are thrilled to support these extraordinary projects through FSR’s Cardiac Sarcoidosis Grant," says Mary McGowan, FSR's CEO. "The insights gained from this research have the potential to revolutionize the diagnosis, outcome evaluation, and treatment strategies not only for individuals with cardiac sarcoidosis but also for a wide range of other inflammatory diseases." FSR is dedicated to accelerating sarcoidosis research through its fellowships, pilot and cardiac grants, and other disease-specific initiatives. To date, FSR has provided more than $7 million in funding to support sarcoidosis research worldwide. To learn more about FSR’s funding opportunities, visit https://www.stopsarcoidosis.org/fsr-grants/ . About Sarcoidosis Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. Despite advances in research, sarcoidosis remains challenging to diagnose, with limited treatment options and no known cure. Approximately 175,000 people live with sarcoidosis in the United States. About the Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR) is the leading international organization dedicated to finding a cure for sarcoidosis and improving care for those living with the disease through research, education, and support. For more information about FSR and its community programs, visit: www.stopsarcoidosis.org . Media contact: Cathi Davis Director of Communications and Marketing 312-341-0500 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e117b7a-964e-442d-b5ed-d7fff74c93b9Paylocity director Steven Sarowitz sells $603,704 in stock
Terrell Owens Takes Massive Shot at Brett Favre Over Alleged Money Stealing Scandal